U.S., EUROPE, AND CHINA MYELODYSPLASTIC SYNDROME (MDS) TREATMENT MARKE ANALYSIS

U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment MarkeSize and Trends

The U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market is estimated to be valued at US$ 2,042.6 Mn in 2020 and is expected to reach US$ 3,404.1 Mn by 2027, exhibiting a CAGR of 7.6% over the forecast period (2020-2027).

Figure 1. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2016-2027

The growing effort to introduce highly effective therapies for various MDS types is expected to drive the market growth over the forecast period.  

The rising efforts made by pharmaceutical companies to introduce highly effective therapies for MDS is a major factor that is expected to drive growth of the U.S., Europe, and China Myelodysplastic Syndrome (MDS) treatment market over the forecast period. Moreover, increasing knowledge regarding the disease and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of the MDS are supporting the market growth. Key pharmaceutical organizations in the U.S, Europe, and China myelodysplastic syndrome (MDS) treatment market such as Celgene are focusing on research and development (R&D) of MDS specific drugs and several of their drugs are showing potential in the clinical trials. For instance, in July 2018, Celgene (a part of Bristol Myers Squibb) and Acceleron collaborated and announced that luspatercept which is a medication used in the management and treatment of anemia in myelodysplastic syndromes, achieved all primary and key secondary endpoints in the phase III MEDALIST and BELIEVE trials in patients with low-to-intermediate risk myelodysplastic syndrome (MDS) and transfusion-dependent beta thalassemia, respectively.

Figure 2. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market Share (%), by Drugs, 2020

Market Trends

Rising public awareness about myelodysplastic syndromes (MDS) and its early diagnosis and availability of new treatment options for MDS are expected to drive the market growth over the forecast period. Moreover, early diagnosis of MDS is important because it significantly increases the quality of life in patients by early treatment, it also reduces the chances of recurrent blood transfusion and, in more severe cases, as in 30% of the time, it can prohibit the evolution of the MDS disease into leukemia. Government organizations and drug manufacturing companies are focusing on spreading awareness about MDS by providing funding and conducting awareness programs.

Market Trends

Rising public awareness about myelodysplastic syndromes (MDS) and its early diagnosis and availability of new treatment options for MDS are expected to drive growth of the market over the forecast period. Moreover, early diagnosis of MDS is important because it significantly increases the quality of life in patients by early treatment, it also reduces the chances of recurrent blood transfusion and in more severe cases, as in 30% of the time, it can prohibit the evolution of the MDS disease into leukemia. Government organizations and drug manufacturing companies are focusing on spreading awareness about MDS by providing funding and conducting awareness programs. For instance, in October 2018, Grupo Biotoscana, a Latin American (Headquartered in Montevideo, Uruguay and with presence in 10 countries throughout the region) biopharmaceutical company conducted campaign to honor Myelodysplastic Syndrome World Awareness Day, which is celebrated on October 25. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about disease throughout the October month.